Symbiotix Biotherapies
Boston
About Symbiotix Biotherapies
Symbiotix Biotherapies is a provider of a novel class of molecular therapeutics intended to develop molecules.The company's novel class of molecular therapeutics include a novel class of Treg-modulating therapeutics based on molecules derived from the human microbiom, enabling patients access first-in-class oral agents that improves their lives and helps them to treat themselves of inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $9.3M
- Last round: Series Unknown (Nov 2017)
- Website: symbiotix-bio.com
- Phone: (617) 535-3196
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/symbiotix-biotherapies-147783 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.